Cabotegravir And Rilpivirine: Efficacy and Safety Study


Ezintsha is a division of the Wits Health Consortium (WHC), a proprietary limited entity that is owned by the University of the Witwatersrand, based in Johannesburg, South Africa. The entity was established over 3 years ago as a branch off from Wits Reproductive and HIV Institute (WRHI), also a division of WHC.

Prof Francois Venter, who is the founder and Divisional Director of Ezintsha has led large PEPFAR-funded HIV programmes in South Africa, focusing on different key and at-risk populations. A physician by training with expertise in HIV programme implementation, Prof. Venter leads multiple antiretroviral treatment optimisation studies and his work involves health systems research that directly translates into national programmes.

True to its founder and history, Ezintsha has conducted multiple studies that focused on treatment optimization (the ADVANCE trial and other HIV studies, COVID-19 prophylaxis and early treatment studies), diagnostics, monitoring and management systems, technologically-enabled clinical research innovations as well as chronic diseases.

We harness our networks and work closely with both global and local partners including a strong community engagement platform to bring about solutions to health problems.

 As South African academics and health professionals who apply innovation to health-related problems, the group at Ezintsha works to extend access to effective drugs so that quality health care and medicine is available to everyone. This coupled with a large database of people living with HIV from the previously completed studies, Ezintsha has been able to successfully recruit for the CARES study.

Dr. Simiso Sokhela
Site PI